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Treatment with an oral small molecule inhibitor of
P selectin (PSI-697) decreases vein wall injury in a
rat stenosis model of venous thrombosis
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Background: Vein wall injury after thrombosis is multifactorial but seems dependent on thrombus and local thrombotic
and inflammatory mechanisms. We hypothesized that inhibition of vein wall injury through reduction of thrombotic and
inflammatory events with P-selectin inhibition and/or low-molecular-weight heparin (LMWH) occurs independently of
thrombus resolution in a rat model of venous thrombosis.
Methods: Male rats underwent inferior vena cava (IVC) stenosis (94.4%  0.5% reduction in IVC diameter) to induce
thrombosis. Rats were treated from 2 days after thrombosis until they were killed 7 days later. Groups consisted of (1)
PSI-697, a P-selectin inhibitor (30 mg/kg; oral gavage daily); (2) LMWH-Lovenox (LOV; enoxaparin) 3 mg/kg
subcutaneously daily; (3) PSI-697 (30 mg/kg; oral gavage daily) plus LOV 3mg/kg subcutaneously daily (PSI LOV);
(4) and untreated controls. Evaluations included thrombus mass, vein wall tensiometry (stiffness [inverse of compli-
ance]), intimal thickness scoring by light microscopy, vein wall inflammatory mediators by enzyme-linked immunosor-
bent assay, and vein wall inflammatory cells by histologic evaluation.
Results: Thrombus mass was not reduced by any treatment. Animals treated with PSI-697 alone, LOV alone, or PSI 
LOV demonstrated significant decreases in vein wall stiffness when compared with controls. The vein wall stiffness of the
PSI-697–treated groups was also significantly lower than in the LOV-only group. Animals treated with PSI-697 showed
a significantly decreased intimal thickness score when compared with vehicle control IVCs. Vein wall intimal thickening
was also significantly decreased in animals treated with PSI-697 vs LOV. The PSI-697 and PSI LOV groupsmanifested
significant decreases in the immunoregulatory and inflammatory cytokine interleukin 13 as compared with controls and
LOV. Vein wall monocyte chemotactic protein 1 levels were also significantly reduced in the PSI-697 and PSI  LOV
groups vs control. Only PSI-697 significantly decreased vein wall levels of platelet-derived growth factor . Both the
LOV and PSI  LOV groups had significant increases in vein wall monocytes and total inflammatory cells vs controls.
Conclusions: These data suggest that both LMWH and PSI-697 inhibit vein wall injury independently of thrombus mass.
P-selectin inhibition seemed superior to LMWH in measured parameters of injury and mediator inhibition. (J Vasc Surg
2006;44:625-32.)
Clinical Relevance:Deep venous thrombosis (DVT) remains a serious health care problem in this country, affecting more
than 250,000 patients annually. Chronic venous insufficiency, a major complication of DVT, promotes the impairment
of venous outflow, loss of vein compliance, and valvular dysfunction. The current standard of care for both treatment and
prophylaxis of DVT is low-molecular-weight heparin. However, this therapy confers a bleeding risk and does not
protect against postthrombotic syndrome. In previous rat studies, using a recombinant P-selectin receptor antagonist
(rPSGL-Ig) 2 days after thrombosis resulted in less vein wall fibrosis without a decrease in thrombus mass. Further
studies in the rat model of DVT have shown that P-selectin inhibition also inhibits profibrotic cytokine production and
vein wall collagen. This study evaluated the effects of P-selectin inhibition by using a novel oral agent (PSI-697) on the
postthrombotic vein wall and compared this with the current standard of care.
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care problem in this country, with more than 250,000
patients affected and at least 200,000 diagnosed annu-
ally.1-3 Treatment costs to the US health care system
reach billions of dollars per year just for the acute treat-
ment of venous thrombosis, without consideration of
additional costs for treatment of the sequelae of DVT
(chronic venous insufficiency) and pulmonary embolism
(chronic pulmonary hypertension).4-6 Chronic venous
insufficiency, a major complication of DVT, affects be-
tween 400,000 and 500,000 patients with skin ulcer-
ations and 6 to 7 million patients with manifestations of
chronic venous disease, including impairment of venous
outflow, thickened vein walls, and valvular dysfunc-
tion.7-10
Stewart et al11 originally hypothesized that procoagu-
lant events could promote thrombosis by the activation of
leukocytes and platelets. These prothrombotic events initi-
ate the adherence and layering of leukocytes and platelets
on the thrombus, thus leading to amplification and endo-
thelial cell damage. Recent studies using multiple animal
models of thrombosis have shown that the inhibition of P
selectin/P-selectin ligand (PSGL-1) interactions by anti-
body, soluble ligand binding, or small molecule inhibition
can decrease thrombosis without modulating inflammatory
cell extravasation.12-19 Further studies in the rat model of
DVT have shown that P-selectin inhibition also inhibits
profibrotic cytokine and vein wall collagen production.13,20
The current standard of care for both treatment and
prophylaxis of DVT is low-molecular-weight heparin
(LMWH).21 This is effective therapy but does confer a
bleeding risk, and it is unclear whether this agent decreases
vein wall damage beyond preventing further thrombosis.
This study evaluated the effects of P-selectin inhibition by
using a novel oral agent (PSI-697; Wyeth Research, Cam-
bridge, Mass) on the postthrombotic vein wall and com-
pared this with the current standard of care, LMWH. It also
evaluated the associated profibrotic mediators and leuko-
cyte changes. In previous mouse19 and primate22 studies,
PSI-697 was found to decrease thrombosis when present at
the time thrombi were induced. However, previous rat
studies with a recombinant P-selectin receptor antagonist
(rPSGL-Ig) begun 2 days after thrombus induction re-
sulted in less vein wall fibrosis without a decrease in throm-
bus mass.13,20 We chose to study PSI-697 in a similar rat
model starting treatment 2 days after thrombus induction.
We hypothesized that inhibition of P selectin with PSI-697
would reduce vein wall injury and the sequela of venous
thrombosis independently of thrombus resolution.
METHODS
Sprague-Dawley rats (n 79) underwent inferior vena
cava (IVC) stenosis (94%  0.5% reduction in IVC diame-
ter) to induce thrombosis. This model is similar to that used
in studies of thrombus resolution emphasizing the impor-
tance of monocytes and tissue-type plasminogen activa-
tor.23,24 In brief, rats are anesthetized with isoflurane gas
via nose cone and undergo a midline laparotomy. The IVCis directly approached by blunt dissection. A 6-0 nonreac-
tive ligature is placed on the IVC just below the level of the
renal veins and tightened down on a 3-0 silk suture until an
average 94% 0.5% reduction in IVC diameter is achieved
(as determined by ultrasound imaging; three rats per
group; unpublished observation by Wrobleski, SK; Fig 1).
The 3-0 silk suture is then immediately removed once the
IVC stenosis has been created.
Rats were treated daily, starting 2 days after thrombo-
sis, and were killed 7 days later for tissue evaluation. Groups
consisted of (1) PSI-697 inhibitor (30 mg/kg; oral gavage
daily), (2) LMWH-Lovenox (LOV; enoxaparin; Aventis-
Pharma, Bridgewater, NJ) 3 mg/kg subcutaneously daily;
(3) PSI-697 inhibitor (30 mg/kg; oral gavage daily) plus
LOV3mg/kg subcutaneously daily (PSILOV); (4), and
untreated vehicle controls (Fig 2). Additionally, a group of
animals that did not undergo any surgical manipulation was
included (normal animals) to provide a baseline for tensiom-
etry and chemokine/cytokine levels. The dose of PSI-697
30 mg · kg1 · d1 was based on the effective oral dose
determined in a model of rat carotid balloon injury,23
whereas the dose of enoxaparin was the amount that pro-
duced therapeutic anticoagulation in rats from previous
studies.
P-selectin inhibition. PSI-697 is an approximately
370-MW organic small molecule inhibitor of P selectin.
This compound has been demonstrated in vitro to disrupt
the binding of P selectin to its ligand PSGL-1 and to reduce
white cell rolling in the microvasculature of mice.23 This
oral formulation has been shown to significantly decrease
thrombosis in a mouse and primate model of venous
thrombosis.19,22 Rats in this study were dosed with an oral
suspension of PSI-697 at 30 mg/kg daily by using an
18-gauge 3-inch straight 2.25-mm-ball feeding needle
(Biomedical Needles; Popper and Sons, Inc, New Hyde
Park, NY). The peak circulating concentration of PSI-697
was 2400 ng/mL at 135 minutes after initial dosing in our
rodent model. The serum trough concentration of PSI-
697, 24 hours after the last dose, was 28.4  11 ng/mL.
Thrombus mass. The technique (weight/length mea-
sured) used is an indirect measure of thrombus dissolution
over time. At death, the IVC with its associated thrombus
is removed and weighed together and measured for
length.27-29 In prior work, thrombus mass has been found
to correlate with thrombus weight (thrombus evaluation
independent of length).30
Vein wall tensiometric analysis. Tensiometry mea-
surements were made of individual IVC samples in this
study to evaluate themechanical properties (stiffness) of the
vein wall after thrombosis.29 Harvested vein samples were
divided longitudinally, placed in phosphate-buffered saline,
and kept on ice until tensiometry testing (Mechanical Test-
ing Equipment 5542 series; Instron Corp, Norwood,
Mass). Each vein sample was mounted into the load frame
by using pneumatic grippers, and force was applied to
failure, with forces in newtons and length determined to
yield a stiffness value. The results of each test were recorded
via a computer program (Merlin Materials Testing Soft-
) sten
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was recorded in millimeters and recorded (stiffness).
Intimal thickness scoring. Paraffin-embedded IVC
tissue was sectioned (3 mm) and stained with hematoxylin
and eosin. By using light microscopy in a blinded fashion,
intimal thickness (IT) was scored in the following fashion,
encompassing five segments around the circumference of
the vein:
0. Intima appears as just a potential space with space occu-
pied only by endothelial cells.
1. Very small spaces are present between endothelial cells
and the internal elastic lamina. Intima still appears gen-
erally as thick as the nuclei of normal spindle-shaped
endothelial cells.
2. Intima is at least twice as thick as an endothelial nucleus
at its widest point in the high-power field.
3. Intima is at least five times the thickness of a red blood
cell diameter at its widest point in the high-power field.
IT tends to be highly variable and may contain cells
Fig 1. Rat inferior vena cava (IVC
Fig 2. Study design using the rat stenosis model of deep venous
thrombosis. IVC, Inferior vena cava.other than endothelial cells.4. Intima is greatly thickened and contains fibroblasts,
white blood cells, and/or hemorrhage at its widest
point.
Vein wall morphometrics. The IVC samples were
paraffin-embedded, stained with hematoxylin and eosin,
and examined under high-power oil immersion light mi-
croscopy (1000). Five representative high-power fields
were examined around the vein wall, and the cell counts
were analyzed; cells were identified as polymorphonuclear
cells, monocyte/macrophages, or lymphocytes on the basis
of standard histologic criteria, including nuclear size, cyto-
plasmic content, and total cell size, in a blinded fashion by
a board-certified pathologist.26-28
Antigen determination. Enzyme-linked immunosor-
bent assay was used to determine vein wall total tissue
protein concentrations of interleukin (IL)-13, monocyte
chemotactic protein (MCP)-1, and platelet-derived growth
factor (PDGF)- (R&D Systems, Minneapolis, Minn).
Analysis was made with the thrombus removed. In brief, all
samples were run in duplicate on freshly homogenized vein
wall tissue, with homogenization performed in complete
protease inhibitor cocktail (Roche, Mannheim, Germany).
The suspension was sonicated on ice for 30 seconds and
centrifuged at 14,000 rpm for 10 minutes, and the super-
natant was used to run the tests. Samples were added and
detected by a biotinylated detection antibody, followed
by tetramethylbenzadine (TMB) substrate. The color reac-
tion was stopped with 1 mol/L phosphoric acid, and the
plates are read on a Plate Reader Elx808 (Biotek,Winooski,
osis model of venous thrombosis.VT) at a 450-nm wavelength. Total protein was measured
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colorimetric detection and quantitation of total protein,
read at 590 nm (Pierce, Rockford, Ill).
Statistical evaluation and animal use. Statistical anal-
ysis included mean  SEM, analysis of variance, and un-
paired Student t tests for parametric data (SPSS SigmaStat
2.03, Aspire Software International, Leesburg, Va). Signif-
icance was defined as P  .05. The health status of all
animals was monitored, and all animals were free of patho-
gens. All rats were housed and cared for by the University
of Michigan Unit for Laboratory Animal Medicine. The
University of Michigan is an American Association for
Accreditation of Laboratory Animal Care–accredited facil-
ity under the direction of a veterinarian according to the
Principles of Laboratory Animal Care (formulated by the
National Society for Medical Research) and the Guide for
the Care andUse of Laboratory Animals (National Academy
of Sciences, 1996). TheUniversity ofMichigan Committee
on Use and Care of Animals approved this research
protocol.
RESULTS
Thrombosis is not altered with treatments. Thrombus
mass is a reliable measure of normal thrombus dissolu-
tion.11-14,16 No treatment regimen had a significant effect
of decreasing thrombus mass compared with controls. Val-
ues were as follows: control, 0.051  0.003  104 g/cm;
PSI-697, 0.059  0.006  104 g/cm; LOV, 0.057 
0.007 104 g/cm; and PSI LOV, 0.053 0.007 104
g/cm. This model of thrombosis produced a significant
thrombosis that was five times greater than in normal
animals, which did not have venous thrombi present (nor-
mal animals, 0.014  0.001  104 g/cm).
Vein wall stiffness is decreased with P-selectin
inhibition and LMWH after thrombosis. The vein
wall stiffness of animals treated with PSI-697 had measure-
ments nearest to those of nonthrombosed normal animals,
whereas animals treated with PSI-697 after thrombosis
showed a significant decrease (P .01) in vein wall stiffness
compared with vehicle control by nearly fourfold. The
LMWH treatment was associated with a significant reduc-
tion (P  .05) of stiffness as compared with the vehicle
controls, with a nearly twofold decrease in vein wall stiff-
ness, whereas the combination group of PSI  LOV also
showed significantly decreased vein wall stiffness (P 
.002). When direct comparison was made between groups
treated with PSI-697 and LOV, PSI-697 treatment was
associated with significantly less vein wall stiffness (P .05;
Fig 3).
Only P-selectin inhibition reduces vein wall IT after
thrombosis. Vein wall injury is accompanied by IT.22-29
To assess the effects of P-selectin inhibition and LMWHon
vein wall intimal response, IT was evaluated histologically.
Animals treated with PSI-697 showed a significantly de-
creased IT score when compared with vehicle control IVCs.
Vein wall IT was also significantly decreased in animals
treated with PSI-697 vs LOV. No other significant differ-
ences were noted between groups, and the combination ofPSI  LOV was not associated with significantly less IT
(Fig 4).
Both P-selectin inhibition and the combination of
PSI-697 plus LMWH decrease profibrotic vein wall
mediators. Vein wall homogenates from animals treated
with PSI-697 had significantly decreased IL-13 antigen
levels when compared with controls (P  .003). The com-
bination treatment of PSI  LOV was also associated with
significantly decreased IL-13 levels vs control animals (P
.007). As compared with LOV alone, PSI-697 and (P 
.007) and PSI  LOV (P  .012) treatments also signifi-
cantly decreased IL-13 antigen levels (Fig 5, A).
The immunoregulatory cytokine MCP-1 is responsible
for the recruitment of monocytes to sites of injury and
inflammation and was significantly decreased, by 52% (P
.011), in vein wall homogenates from animals treated with
PSI-697 when compared with thrombosed controls. The
combination therapy of PSI  LOV was also associated
with significantly decreased MCP-1 antigen levels (P 
.02). LOV treatment itself was not associated with de-
creased MCP-1 in the vein wall after thrombosis (Fig 5, B).
PDGF is produced by a number of cell types and
Fig 3. Vein wall tensiometric analysis. LOV, Lovenox (enoxapa-
rin); CTR, control; NORM, normal.
Fig 4. Vein wall intimal thickness scoring. LOV, Lovenox (enox-
aparin); CTR, control.elements, including platelets that promote the migration of
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 3 Myers et al 629monocytes, fibroblasts, and smooth muscle cells to areas of
injury. Only animals treated with PSI-697 had significantly
decreased vein wall levels of PDGF- when compared
with controls (P  .041), and neither LOV alone nor in
combination with PSI-697 was associated with a significant
decrease (Fig 5, C).
Vein wall leukocytes are increased with LMWH
but not P-selectin inhibition by visual cell counting.
P-selectin inhibition by PSI-697 did not decrease the num-
ber of vein wall inflammatory cells compared with throm-
bosed controls. LOV treatment was associated with sig-
nificantly increased numbers of vein wall monocyte/
macrophages by nearly 2-fold (P  .007) and with total
inflammatory cell populations by 1.5-fold (P .026) when
compared with thrombosed controls. Animals treated with
the combination PSI  LOV also had significantly in-
creased monocyte/macrophages (P  .003), lymphocytes
(P  .003), and total inflammatory cells (P  .001) in the
vein wall compared with thrombosed controls (Fig 6).
DISCUSSION
The occurrence of DVT and the sequela of chronic
venous insufficiency remains a significant and underappre-
ciated heath care problem. New and safer therapies are
Fig 5. A, Vein wall interleukin 13 antigen levels. LOV
Vein wall monocyte chemotactic protein 1/JE (MCP-1/
 (PDGF-BB) antigen levels.needed to treat DVT. In this study, the novel findingsinclude the fact that vein wall injury was most significantly
attenuated by the small molecule inhibitor of P selectin
(PSI-697) in a rodent stenosis model of venous thrombo-
enox (enoxaparin); CTR, control; NORM, normal. B,
tigen levels. C, Vein wall platelet-derived growth factor
Fig 6. Vein wall morphometrics. LOV, Lovenox (enoxaparin);
CTR, control; TC, total inflammatory cell; MONO, monocytes;
LYMPH, lymphocytes; PMN, polymorphonuclear cells; HPF,
high-power field., Lov
JE) ansis. The data suggest that this effect is independent of
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anti-inflammatory effects on the vein wall. Support for this
notion derives from the observation that profibrotic medi-
ators such as IL-13, MCP-1, and PDGF- were signifi-
cantly decreased with PSI-697 treatment. Lesser, but still
significant, reductions in vein wall injury were also observed
with LMWH, and this serves to confirm our prior work
(although at a lower dose and a different LMWH prepara-
tion) showing that LMWH decreased perithrombotic vein
wall inflammation.31
On venous endothelial cell stimulation, PSGL-1 ligand
initiates the adhesion interactions responsible for the
initial rolling of neutrophils along stimulated vascular en-
dothelium, thus creating platelet-leukocyte complexes on
the vascular surface and in the circulation.25-33 Targeted
P-selectin inhibition has been shown to modulate throm-
bogenesis by counteracting platelet-endothelial, platelet-
platelet, and platelet-leukocyte interactions in several ani-
mal models of venous thrombosis. Although in this study,
treatment after thrombosis did not decrease overall throm-
bus mass, we have noted that P-selectin inhibition in the
primate after the thrombus has been present for 48 hours
still results in less thrombus burden over time.18 The dif-
ference may relate to the type of animal species studied (rat
vs baboon) or to the model used. The primate model
involves temporary balloon occlusion to form thrombosis
without vessel ligation and stenosis, whereas the current rat
model involved a significant 94% stenosis to produce
thrombosis. We chose the stenosis model in the rat to align
with models in the literature that have been used to evalu-
ate thrombus resolution.25,26 The advantages of this model
include but are not limited to the fact that clinical DVT
often begins as a nonocclusive event that then progresses to
occlusion (as in the current rat protocol).
It has been suggested that the inhibition of platelet-
leukocyte interactions modulates the release of PDGFs and
proteases, with promotion of vein remodeling and fibro-
sis.34-36 Previous work in our laboratory showed that low-
dose LMWH demonstrated anti-inflammatory properties
during stasis-induced thrombosis.31 However, LMWHs
have decreased inhibitory effects on both P- and L-selectin
ligand binding as compared with standard unfractionated
heparin,21,37,38 and this may be why no difference in pro-
fibrotic mediators was observed with LMWH. Addition-
ally, in our previous study, there was no inflammatory
protection at the anticoagulant dose of LMWH, which is
closer to the dose used in this study.
Vein wall injury was primarily reflected by measuring
vein wall stiffness, a biomechanical measure. Our findings
showed that daily treatment with PSI-697, LMWH, or
PSI-697 in combination with LMWH was associated with
decreased vein wall stiffness, independently of thrombus
size (Fig 3).
Prior work has suggested that less vein wall collagen
occurs with P-selectin inhibition,20 and in this study a
complementary parameter of intimal injury (IT) was deter-
mined. However, only PSI-697 had associated decreased
IT scores when compared with thrombosed controls. IT iswell established to occur after arterial injury and is related to
selectin interactions.36 Stiffness is related to vein wall injury
conferred by proteinases,29 whereas vein IT may be more
related to levels of profibrotic mediators, such as IL-13.
This study did not confirm the specific downstream
signaling mechanisms associated with the antifibrotic prop-
erties of PSI-697. However, the evaluation of proinflam-
matory mediators from vein wall homogenates showed that
P-selectin inhibition significantly decreased vein wall anti-
gen levels of IL-13, MCP-1, and PDGF-. Treatment
with LMWH alone was not associated with reduced levels.
The relationship between IL-13 and fibrosis has been
shown in animal models of pulmonary fibrosis and visceral
parasitic migrations.39 IL-13 is released from activated
T-helper lymphocytes and promotes the expression of
MCP-1, a chemokine that directs monocytes to areas of
inflammation.29,40 It is interesting to note that IL-13 and
MCP-1 elevations were found in pulmonary tissue after
pulmonary embolism in a rat model and were associated
with significant intimal hyperplasia.41 Although MCP-1
may confer organ fibrosis, it may also hasten DVT resolu-
tion when infused into the thrombus.24
Similarly, activated platelets have been shown to release
PDGF which was increased in thrombosed control vein
walls.42 PDGF is active in signaling that occurs in wound
healing and is implicated in atherosclerosis, fibrotic disease,
and cancer.43-45 It is likely that the decreased IT in rats
treated with PSI-697 was related to significantly less
PDGF- present.
Of interest, animals treated with LMWH alone and in
combination with PSI-697 had a significant increase in
monocyte/macrophage populations and overall total num-
bers of inflammatory cells present in the vein wall (Fig 6).
Conversely, animals treated with PSI-697 had inflamma-
tory cell populations similar to those of untreated controls
by visual counting. It is not clear from this study whether
the decreased MCP-1 is causative of fewer monocytes or is
a secondary marker of fewer leukocytes in the vein wall.
These observations support similar findings in which P-
selectin inhibition did not decrease the vein wall extravasa-
tion of inflammatory cells in the presence of thrombosis.16
A recent study by Henke et al29 suggests a temporally
important relationship between neutrophil migration and
vein wall injury response—namely, that the early cellular
composition affects how the vein wall remodels, indepen-
dently of thrombus size. The presence of neutrophils in the
vein wall seems to be important to limit vein wall fibrosis.
Taken together, these data suggest that both LMWH
and PSI-697 inhibit vein wall injury independently of
thrombus size in a rodent model of DVT. P-selectin inhi-
bition with PSI-697 seems superior to LMWH or the
combination regarding vein wall stiffness, the production
of proinflammatory cytokines, and IT scoring. PSI-697
with LOV did not have a greater response than PSI-697
administered alone and in some instances (IT, PDGF-
levels, and cell infiltrates) did not exhibit a beneficial re-
sponse. This raises a question about the combination of
these treatments and should be examined in future studies.
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decreases the severity of postthrombotic changes to the
vein wall need to be further elucidated. These results show
the potential benefits of P-selectin inhibition in modulating
the pathophysiological changes in the vein wall that pro-
mote chronic venous insufficiency.
We thank Derek A. Dubay, MD, for his assistance with
vein wall tensiometric measurements.We also thank Robert
E. Sigler, DVM, PhD, for his assistance with vein wall IT
scoring and morphometrics.
AUTHOR CONTRIBUTIONS
Conception and design: DDM, PKH, RGS, TWW
Analysis and interpretation: DDM, PKH, SKW, RGS,
TWW
Data collection: DDM, SKW, AEH, TRM
Writing the article: DDM, PKH, TWW
Critical revision of the article: DDM, PKH, SKW, RGS,
TWW
Final approval of the article: DDM, PKH, SKW, RGS,
TRM, TWW
Statistical analysis: DDM, PKH, TWW
Obtained funding: PWB, NK, GS, TWW
Overall responsibility: DDM
REFERENCES
1. Coon WW. Epidemiology of venous thromboembolism. Ann Surg
1977;186:149-64.
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan
NA, Jovanovic B, et al. A population-based perspective of the hospital
incidence and case-fatality rates of deep vein thrombosis and pulmonary
embolism. The Worcester DVT study. Arch Intern Med 1991;151:
933-8.
3. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM,
O’Fallon WM, et al. The epidemiology of venous thromboembolism in
the community. Thromb Haemost 2001;86:452-63.
4. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM,
Melton LJ III. Trends in the incidence of deep vein thrombosis and
pulmonary embolism. Arch Intern Med 1998;158:585-93.
5. Proctor MC, Greenfield LJ. Pulmonary embolism: diagnosis, incidence
and implications. Cardiovasc Surg 1997;5:77-81.
6. Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep
vein thrombosis with low molecular-weight heparin: outcome of ther-
apy and health economy aspects. Haemostasis 1998;28(Suppl 3):8-16.
7. Deatrick KB, Eliason JI, Lynch EM, Moore AJ, Dewyer NA, Varma
MR, et al. Vein wall remodeling after deep vein thrombosis involves
matrix metalloproteinases and late fibrosis in a mouse model. J Vasc
Surg 2005;42:140-8.
8. Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in
iliofemoral thrombosis: long-term effects on venous hemodynamics,
clinical status and quality of life. Ann Surg 2000;239:118-26.
9. Heit JA. Venous thromboembolism: disease burden, outcomes and risk
factors. J Thromb Haemost 2005;3:1611-7.
10. Nicolaides AN, Fareed J, Kakkar AK, Breddin HK, Goldhaber SZ, Hull
R, et al. Prevention of VTE: international consensus statement (guide-
lines according to scientific evidence). Int Angiol 1997;16:3-38.
11. Stewart GJ, Ritchie WG, Lynch PR. Venous endothelial damage pro-
duced by massive sticking and emigration of leukocytes. Am J Pathol
1974;74:507-32.
12. Wakefield TW, Strieter RM, Downing LJ, Kadell AM, Wilke CA,
Burdick MD, et al. P selectin and TNF inhibition reduce venous
thrombosis inflammation. J Surg Res 1996;64:26-31.13. Myers DD, Henke PK, Wrobleski SK, Hawley AE, Farris DM, Chap-
man AM, et al. P-selectin inhibition enhances thrombus resolution and
decreases vein wall fibrosis in a rat model. J Vasc Surg 2002;36:928-38.
14. Downing LJ, Wakefield TW, Strieter RM, Prince MR, Londy FJ,
Fowlkes JB, et al. Anti-p-selectin antibody decreases inflammation
and thrombus formation in venous thrombosis. J Vasc Surg 1997;25:
816-28.
15. Wakefield TW, Strieter RM, Schaub RG, Myers DD, Prince MR,
Wrobleski SK, et al. Venous thrombosis prophylaxis by inflammatory
inhibition without anticoagulation therapy. J Vasc Surg 2000;31:
309-24.
16. Myers DD Jr, Schaub R, Wrobleski SK, Londy FJ, Fex BA, Chapman
AM, et al. P-selectin antagonism causes dose-dependent venous throm-
bosis inhibition. Thromb Haemost 2001;85:423-9.
17. Myers D, Wrobleski S, Londy F, Fex B, Hawley A, Schaub R, et al. New
and effective treatment of experimentally induced venous thrombosis
with anti-inflammatory rPSGL-Ig. ThrombHaemost 2002;87:374-82.
18. Schaub RG. Inflammation and thrombosis: a 30-year perspective. Vas-
cular Web.org. 2005. Available from http://www.vascularweb.org/
_CONTRIBUTION_PAGES/Resea r ch/Pa s t_Re sea r ch_
Initiatives_Programs/2004_Research_Initiatives/2004_Invited_
Papers/Inflammation_and_Thrombosis_a_30_Year_Perspective_
Schaub.html.
19. Myers DD Jr, Rectenwald JF, Bedard PW, Kaila N, Shaw GD, Schaub
RG, et al. Decreased venous thrombosis with an oral inhibitor of
P-selectin. J Vasc Surg 2005;42:329-36.
20. Thanaporn P, Myers DD Jr, Wrobleski SW, Hawley AE, Farris DM,
Wakefield TW, et al. P-selectin inhibition decreases post-thrombotic
vein wall fibrosis in a rat model. Surgery 2003;134:365-71.
21. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Jonathan L,
Halperin JL, et al. Heparin and low-molecular-weight heparin mecha-
nisms of action, pharmacokinetics, dosing, monitoring, efficacy, and
safety. Chest 2001;119:64-94.
22. Myers D, Wrobleski S, Longo C, Bedard P, Kaila N, Shaw G, et al.
Prophylaxis using a novel oral small molecule inhibitor to the P-selectin
receptor promotes thrombus resolution in a baboon model of venous
thrombosis. J Thromb Haemost 2005;3(Suppl 1):OR390.
23. Bedard PW, Suskova N, EppihimerMJ, Clerin V, Tavares J, Harding K,
et al. A novel P-selectin inhibitor PSI-697 demonstrates positive activity
following oral administration in rodent models of vascular inflamma-
tion. J Thromb Haemost 2005;3(Suppl 1):OR135.
24. Humphries J, McGuinness CL, Smith A, Waltham M, Poston R,
Burnand KG. Monocyte chemotactic protein-1 (MCP-1) accelerates
the organization and resolution of venous thrombi. J Vasc Surg 1999;
30:894-9.
25. Northeast ADR, Soo KS, Bobrow LG, Gaffney PJ, Burnand KG. The
tissue plasminogen activator and urokinase response in vivo during
natural resolution of venous thrombus. J Vasc Surg 1995;22:573-9.
26. Myers DD Jr, Wrobleski SK, Henke PK, Wakefield TW. Coagulation
biology. In: Souba W, Wilmore D, editors. Surgical research. San
Diego: Academic Press; 2001. p. 989-99.
27. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Austin JC, Hare BD,
et al. Interleukin-10 regulates thrombus-induced vein wall inflamma-
tion and thrombosis. J Immunol 1998;161:1471-6.
28. Henke PK, Debrunye LA, Strieter RM, Bromberg JS, Prince MR,
Kadell AM, et al. Viral IL-10 gene transfer decreases inflammation and
cell adhesion molecule expression in rat model of venous thrombosis.
J Immunol 2000;164:2131-41.
29. Henke PK, Varma MR, Deatrick KB, Drewyer NA, Lynch EM, Moore
AJ. Neutrophils modulate post-thrombotic vein wall remodeling but
not thrombus neovascularization. Thromb Haemost 2006;95:1-11.
30. Myers DD Jr, Hawley AE, Farris DM, Wrobleski SW, Thanaporn P,
Schaub RG, et al. P-selectin and leukocyte microparticles potentiate
venous thrombogenesis. J Vasc Surg 2003;38:1075-89.
31. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfield LJ,
Wakefield TW. Low-dose low-molecular-weight heparin is anti-
inflammatory during venous thrombosis. J Vasc Surg 1998;28:848-54.
32. Sullivan VV, Hawley AE, Farris DM, Knipp BS, Varga AJ, Wrobleski
SK, et al. Decrease in fibrin content of venous thrombi in selectin-
deficient mice. J Surg Res 2003;109:1-7.
JOURNAL OF VASCULAR SURGERY
September 2006632 Myers et al33. Hrachovinova´ I, Cambien B, Hafezi-Moghadam A, Kappelmayer J,
Camphausen RT,Widom A, et al. Interaction of P-selectin and PSGL-1
generates microparticles that correct hemostasis in a mouse model of
hemophilia A. Nat Med 2003;9:1020-5.
34. Frenette PS, Wagner DD. Adhesion molecules: part II: blood vessels
and blood cells. N Engl J Med 1996;335:43-5.
35. Walzog B, Seifert R, Zakrzewicz A, Gaehtgens P, Ley K. Cross-linking
of CD18 in human neutrophils induces an increase of intercellular
Ca2, exocytosis of azurophilic granules, quantitative up-regulation of
CD18, shedding of L-selectin, and actin polymerization. J Leukoc Biol
1994;56:625-35.
36. Zeiffer U, Schober A, Lietz M, Liehn EA, Erl W, Emans N, et al.
Neointimal smooth muscle cells display a proinflammatory phenotype
resulting in increased leukocyte recruitment mediated by P-selectin and
chemokines. Circ Res 2004;94:776-84.
37. Wang L, Brown JR, Varki A, Esko DJ. Heparin’s anti-inflammatory
effects require glucosamine 6-O-sulfation and are mediated by blockade
of L- and P-selectins. J Clin Invest 2002;110:127-36.
38. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential
interactions of heparin and heparin sulfate glycosaminoglycans with
the selectins. Implications for the use of unfractionated and low
molecular weight heparins as therapeutic agents. J Clin Invest 1998;
101:877-89.39. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003;21:
425-56.
40. Mentink-Kane MM, Wynn TA. Opposing roles of IL-13 and IL-13
receptor 2 in health and disease. Immunol Rev 2004;202:191-202.
41. Rectenwald JE, Deatrick KB, Sukheepod P, Lynch EM, Moore AJ,
Moaveni DM, et al. Experimental pulmonary embolism: effects of the
thrombus and attenuation of pulmonary artery injury by low-molecular-
weight heparin. J Vasc Surg 2006;43:800-8.
42. Greenhalgh DG, Hummel RP III, Albertson S, Breeden MP. Synergis-
tic actions of platelet-derived growth factor and the insulin-like growth
factors in vivo. Enhancement of tissue repair in genetically diabetic
mice. Wound Repair Regen 1993;1:69-81.
43. Heldin CH, Eriksson U, Ostman A. New members of the platelet-
derived growth factors family mitogens. Arch Biochem Biophys 2002;
398:284-90.
44. Cohen MA, Eaglstein WH. Recombinant human platelet-derived
growth factor gel speeds healing of acute full-thickness punch biopsy
wounds. J Am Acad Dermatol 2001;45:857-62.
45. Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and
human cancer. J Biochem Mol Biol 2003;36:49-59.Submitted Feb 24, 2006; accepted May 11, 2006.
